Transgene SA

Company Profile

• Business description

  Transgene SA is a French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Its clinical-stage programs include a portfolio of viral vector-based immunotherapeutics. The flagship program, TG4050, is an individualized therapeutic vaccine based on the myvac platform. The company also has other viral vector-based programs, including BT-001, an oncolytic virus based on the Invir.IO viral backbone, which is in clinical development. In addition, it conducts discovery and preclinical work, aimed at developing novel immunotherapies.

• Contact

  400, Boulevard Gonthier d’Andernach
  Parc d’Innovation
  Illkirch-Graffenstaden
  Strasbourg67400
  FRA

  T: +33 388279100

  https://www.transgene.fr

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  31 December 2026

  Employees

  167